BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALX-0081: Interim Phase II data

Interim data from 5 patients in the ongoing, single-blind, international Phase II TITAN trial showed that ALX-0081 followed by ALX-0681 inhibited vWF-mediated clotting as measured by a reduction in ristocetin cofactor compared to placebo. The trial is enrolling 110 patients...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >